Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BIO017
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the U.S. Angelman syndrome afflicts 33,071 patients which BIO017 should be able to treat if approved after clinical efficacy data.
Brand Name : BIO017
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
March 30, 2021
Lead Product(s) : BIO017
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?